<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OTO</journal-id>
<journal-id journal-id-type="hwp">spoto</journal-id>
<journal-title>Otolaryngology–Head and Neck Surgery</journal-title>
<issn pub-type="ppub">0194-5998</issn>
<issn pub-type="epub">1097-6817</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0194599811435052</article-id>
<article-id pub-id-type="publisher-id">10.1177_0194599811435052</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Head and Neck Surgery</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Cyclin D1 and FADD as Biomarkers in Head and Neck Squamous Cell Carcinoma</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Rasamny</surname><given-names>Jk J.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0194599811435052">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Allak</surname><given-names>Amir</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0194599811435052">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Krook</surname><given-names>Kaelyn A.</given-names></name>
<xref ref-type="aff" rid="aff1-0194599811435052">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jo</surname><given-names>Vickie Y.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0194599811435052">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Policarpio-Nicolas</surname><given-names>Maria L.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0194599811435052">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sumner</surname><given-names>Heather M.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0194599811435052">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Moskaluk</surname><given-names>Christopher A.</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff2-0194599811435052">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Frierson</surname><given-names>Henry F.</given-names><suffix>Jr</suffix></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0194599811435052">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Jameson</surname><given-names>Mark J.</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0194599811435052">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0194599811435052"><label>1</label>Department of Otolaryngology–Head and Neck Surgery, University of Virginia Health System, Charlottesville, Virginia, USA</aff>
<aff id="aff2-0194599811435052"><label>2</label>Department of Pathology, University of Virginia Health System, Charlottesville, Virginia, USA</aff>
<author-notes>
<corresp id="corresp1-0194599811435052">Mark J. Jameson, MD, PhD, Division of Head and Neck Surgical Oncology, Department of Otolaryngology–Head and Neck Surgery, University of Virginia Health System, PO Box 800713, Charlottesville, VA 22908-0713, USA Email: <email>mark.jameson@virginia.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2012</year>
</pub-date>
<volume>146</volume>
<issue>6</issue>
<fpage>923</fpage>
<lpage>931</lpage>
<history>
<date date-type="received">
<day>2</day>
<month>9</month>
<year>2011</year>
</date>
<date date-type="rev-recd">
<day>21</day>
<month>11</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>12</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© American Academy of Otolaryngology—Head and Neck Surgery Foundation 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">Official journal of the American Academy of Otolaryngology–Head and Neck Surgery Foundation</copyright-holder>
</permissions>
<abstract>
<p><italic>Objective</italic>. Cyclin D1 and FADD (Fas-associated protein with death domain) regulate the cell cycle and apoptosis, respectively, and are located on chromosome 11q13, which is frequently amplified in head and neck squamous cell carcinoma (HNSCC). This study evaluates these proteins as predictors of clinical outcomes for HNSCC.</p>
<p><italic>Study Design</italic>. Historical cohort study.</p>
<p><italic>Setting</italic>. Academic tertiary care center.</p>
<p><italic>Subjects</italic>. Two hundred twenty-two patients with upper aerodigestive HNSCC.</p>
<p><italic>Results</italic>. Patients with tumors that were strongly positive for cyclin D1 and FADD had reduced overall (OS; <italic>P</italic> = .003 and <italic>P</italic> &lt; .001), disease-specific (DSS; <italic>P</italic> = .039 and <italic>P</italic> &lt; .001), and disease-free (DFS; <italic>P</italic> = .026 and <italic>P</italic> &lt; .001) survival, respectively. Together, the 2 markers effectively stratified OS (<italic>P</italic> &lt; .001), DSS (<italic>P</italic> &lt; .001), and DFS (<italic>P</italic> = .002). Strong FADD staining correlated with greater alcohol consumption and varied significantly with primary tumor site: 56% of hypopharynx tumors expressed high levels of FADD but only 7% of glottis tumors. Using Cox regression analysis, FADD and N stage were significant independent predictors of DSS and DFS, whereas cyclin D1, FADD, and N stage were independently significant for OS.</p>
<p><italic>Conclusion</italic>. Cyclin D1 and FADD may have utility as predictors of long-term outcomes for patients with HNSCC. Further study is needed to determine if these proteins predict response to different treatment approaches or assist in selecting patients for multimodality therapy.</p>
</abstract>
<kwd-group>
<kwd>head and neck cancer</kwd>
<kwd>squamous cell carcinoma</kwd>
<kwd>long-term survival</kwd>
<kwd>biomarkers</kwd>
<kwd>cyclin D1</kwd>
<kwd>FADD</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>The prognosis for squamous cell carcinoma (SCC) of the head and neck (HNSCC) has remained stable and relatively poor over recent decades.<sup><xref ref-type="bibr" rid="bibr1-0194599811435052">1</xref></sup> Prognosis and treatment planning are largely predicated on TNM staging and, to a lesser extent, histopathologic findings such as margin status, perineural invasion, and lymphovascular invasion. Recently, the use of biomarkers has begun to improve and individualize prognostic predictions and treatment regimen selection. To date, epidermal growth factor receptor (EGFR) and human papillomavirus (HPV) have been studied extensively as biomarkers for HNSCC.<sup><xref ref-type="bibr" rid="bibr2-0194599811435052">2</xref></sup></p>
<p>Head and neck SCC is associated with recurrent exposure to carcinogens, resulting in the accumulation of DNA damage. Molecular progression models have been developed hypothesizing that 6 to 10 separate genetic mutations typically occur before development of an HNSCC.<sup><xref ref-type="bibr" rid="bibr3-0194599811435052">3</xref><xref ref-type="bibr" rid="bibr4-0194599811435052"/>-<xref ref-type="bibr" rid="bibr5-0194599811435052">5</xref></sup> These mutations may result in activation of proto-oncogenes (eg, EGFR), inactivation of tumor suppressor genes (eg, p53), or cytogenetic changes such as chromosomal losses, gains, or amplifications (eg, 11q13).<sup><xref ref-type="bibr" rid="bibr6-0194599811435052">6</xref></sup> The altered expression of multiple genes on chromosome 11q13 has been correlated with poor prognosis.<sup><xref ref-type="bibr" rid="bibr7-0194599811435052">7</xref><xref ref-type="bibr" rid="bibr8-0194599811435052"/>-<xref ref-type="bibr" rid="bibr9-0194599811435052">9</xref></sup> The genes encoding cyclin D1 and FADD (Fas-associated protein with death domain) are located on chromosome 11q13.</p>
<p>Cyclin D1 plays a pivotal role in cell cycle regulation and is often overexpressed in malignancy. It activates cyclin-dependent kinases 4 (CDK4) and 6 (CDK6), promoting cell cycle progression through the G1-S transition by phosphorylation of the retinoblastoma tumor suppressor protein (Rb) and subsequent activation of the E2F transcription factors. The consequences of cyclin D1 overexpression in HNSCC, specifically oral cavity SCC, have been a subject of debate within the recent literature.<sup><xref ref-type="bibr" rid="bibr10-0194599811435052">10</xref></sup> High cyclin D1 expression has been found to correlate with poorer survival, locoregional control, and distant control in some studies,<sup><xref ref-type="bibr" rid="bibr10-0194599811435052">10</xref><xref ref-type="bibr" rid="bibr11-0194599811435052"/><xref ref-type="bibr" rid="bibr12-0194599811435052"/><xref ref-type="bibr" rid="bibr13-0194599811435052"/>-<xref ref-type="bibr" rid="bibr14-0194599811435052">14</xref></sup> whereas other investigators have found no relationship to outcomes.<sup><xref ref-type="bibr" rid="bibr15-0194599811435052">15</xref><xref ref-type="bibr" rid="bibr16-0194599811435052"/>-<xref ref-type="bibr" rid="bibr17-0194599811435052">17</xref></sup></p>
<p>FADD regulates both apoptosis and proliferation. FADD is a 23-kDa proapoptotic adaptor molecule. It binds multiple death receptors, including Fas and tissue necrosis factor–receptor 1 (TNF-R1), via its C-terminal death domain (DD). It then activates procaspases via its N-terminal death effector domain (DED), triggering apoptosis.<sup><xref ref-type="bibr" rid="bibr18-0194599811435052">18</xref></sup> FADD plays a role in multiple malignancies, including acute myeloid leukemia (AML). In these instances, lack of FADD confers a survival advantage due to resistance to death receptor–mediated apoptosis.<sup><xref ref-type="bibr" rid="bibr19-0194599811435052">19</xref></sup></p>
<p>Given the known association of 11q13 amplification within HNSCC and the correlation of gene products from this locus with poor prognosis, we hypothesized that cyclin D1 and FADD overexpression serve as biomarkers that predict outcomes in HNSCC.</p>
<sec id="section1-0194599811435052" sec-type="methods">
<title>Methods</title>
<sec id="section2-0194599811435052">
<title>Patients</title>
<p>Specimens from 352 patients with HNSCC (upper aerodigestive only) harvested between July 1990 and August 1999 were obtained from the University of Virginia (UVA) Department of Pathology Tissue Archive. A tissue microarray (TMA) was created from these archival specimens as described below. After obtaining approval from the UVA Institutional Review Board for Health Sciences Research, the patients’ medical records were assessed for pertinent clinical information. Patients were excluded from the study for the following reasons: unknown primary tumors (specimens from nodal tissue only), second primary tumor and/or metastatic disease on presentation, incomplete medical record (particularly staging data), treatment elsewhere, incomplete treatment, no follow-up after completion of treatment, or an inadequate amount of tumor tissue in the TMA cores to obtain accurate immunohistochemistry (IHC) results for both cyclin D1 and FADD. Ultimately, 222 patients were evaluable.</p>
</sec>
<sec id="section3-0194599811435052">
<title>Tissue Microarray and Immunohistochemistry</title>
<p>Tissue microarrays containing four 0.6-mm cores from zinc formalin-fixed, paraffin-embedded blocks from each patient’s tumor were constructed using a Tissue Microarrayer (Beecher Instruments, Silver Spring, Maryland). For IHC on the tissue microarrays, the avidin-biotin immunoperoxidase method was performed. After slides had been placed in a citrate buffer (pH 6.0) and treated with either pressure cooker or microwave heat, each primary antibody was applied for 1 hour. The primary antibodies included anti–cyclin D1 (rabbit monoclonal; clone SP4; 1:50 dilution; Thermo Scientific, Waltham, Massachusetts) and anti-FADD (mouse monoclonal; clone A66-2; 1:100 dilution; BD Pharmingen, San Diego, California). These antibodies are well-characterized commercial products that have been validated in other studies and show a high degree of specificity.<sup><xref ref-type="bibr" rid="bibr20-0194599811435052">20</xref>,<xref ref-type="bibr" rid="bibr21-0194599811435052">21</xref></sup> DAB was used as the chromogen. All scoring was performed by a highly experienced surgical pathologist (HFF), who had no knowledge of the clinical outcomes. Scoring for cyclin D1 was based on percentage of positive cells using the following scale: 0 (no positive cells), 1+ (1%-5% positive), 2+ (6%-50%), and 3+ (&gt;50%) (<xref ref-type="fig" rid="fig1-0194599811435052"><bold>Figure 1A</bold></xref>-<xref ref-type="fig" rid="fig1-0194599811435052"><bold>D</bold></xref>). For clinical correlations, 0 and 1+ staining were coded as “low” expression, and 2+ and 3+ staining were coded as “high” expression. For FADD, because staining was diffuse and, when present, included essentially all tumor cells, scoring was based on overall intensity using the following scale: 0 (no staining), 1+ (weak), 2+ (moderate), and 3+ (strong) (<xref ref-type="fig" rid="fig1-0194599811435052"><bold>Figure 1E</bold></xref>-<xref ref-type="fig" rid="fig1-0194599811435052"><bold>H</bold></xref>). For clinical correlations, 0, 1+, and 2+ staining were coded as “low” expression, and 3+ staining was coded as “high” expression. Negative controls were performed by omitting the primary antibody; these showed no staining in all cases.</p>
<fig id="fig1-0194599811435052" position="float">
<label>Figure 1.</label>
<caption>
<p>Immunohistochemical staining of tissue microarray. Immunoperoxidase technique as described in Methods, magnification ×100. Cyclin D1: (A) 0, (B) 1+, (C) 2+, (D) 3+. FADD: (E) 0, (F) 1+, (G) 2+, (H) 3+.</p>
</caption>
<graphic xlink:href="10.1177_0194599811435052-fig1.tif"/>
</fig>
</sec>
<sec id="section4-0194599811435052">
<title>Clinical Data Collection</title>
<p>Patient, tumor, treatment, and outcome data were collected and recorded. Tumor TNM staging was determined from physical examination, pretreatment imaging, and staging endoscopy. For survival analyses, the time interval was calculated from the final day of treatment, which was the last day of radiotherapy or the day of surgery, depending on the patient. Time to recurrence, metastasis, and secondary tumors were calculated from this date. Average follow-up from completion of therapy was 4.8 years (range, 0.02-19.8 years; median 3.1 years). Any history of tobacco use was recorded (yes/no), as were the number of pack-years. Alcohol use was scored as follows: none, rare (less than 1 drink/d), moderate (1-2 drinks/d), heavy (more than 2 drinks/d), or history/quit.</p>
</sec>
<sec id="section5-0194599811435052">
<title>Statistical Analysis</title>
<p>Differences in patient and tumor characteristics were evaluated by the Student <italic>t</italic> test or χ<sup>2</sup> test as appropriate. These analyses were performed using standard statistical functions in Microsoft Excel 2010 (Microsoft, Redmond, Washington). Kaplan-Meier survival curves were created in IBM SPSS Statistics 19 (SPSS, Inc, an IBM Company, Chicago, Illinois); the same software was used to perform log-rank tests and Cox regressions on survival curves to determine statistically significant differences for single and multiple parameters, respectively. Disease-free survival (DFS) was defined as the time between the date of treatment completion and the date of first recurrence or death from any cause. Living patients without evidence of recurrence were censored at the date of last follow-up. Disease-specific survival (DSS) was defined as the time between the date of treatment completion and the date of death from disease. Patients who died with disease present were assumed to have died as a result of their HNSCC. Patients who died without evidence of disease were censored at the time of death. Living patients without evidence of disease were censored at the date of last follow-up. Overall survival (OS) was defined as the time between the date of treatment completion and the date of death from any cause. Living patients were censored at the date of last follow-up. All statistical results were considered significant at <italic>P</italic> ≤ .05.</p>
</sec>
</sec>
<sec id="section6-0194599811435052" sec-type="results">
<title>Results</title>
<sec id="section7-0194599811435052">
<title>Patient and Tumor Characteristics</title>
<p>Patient and tumor characteristics are shown in <xref ref-type="table" rid="table1-0194599811435052"><bold>Tables 1</bold></xref> and <xref ref-type="table" rid="table2-0194599811435052"><bold>2</bold></xref>. Distributions of characteristics are shown for the entire cohort and the low- and high-expressing subgroups of cyclin D1 and FADD expression. In total, 222 patients were evaluable. Data on cyclin D1 expression were available for 215 patients; 56 (26.0%) demonstrated low expression, and 159 (74.0%) showed high expression. For FADD expression, data were available on all 222 patients; 164 (73.9%) were low expressers, and 58 (26.1%) were high expressers.</p>
<table-wrap id="table1-0194599811435052" position="float">
<label>Table 1.</label>
<caption>
<p>Patient Characteristics</p>
</caption>
<graphic alternate-form-of="table1-0194599811435052" xlink:href="10.1177_0194599811435052-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th align="center" colspan="3">Cyclin D1 Expression (n = 215)</th>
<th align="center" colspan="3">FADD Expression (n = 222)</th>
</tr>
<tr>
<th/>
<th align="center">All</th>
<th align="center">Low</th>
<th align="center">High</th>
<th align="center"><italic>P</italic> Value</th>
<th align="center">Low</th>
<th align="center">High</th>
<th align="center"><italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients, No. (%)</td>
<td>222 (100.0)</td>
<td>56 (26.0)</td>
<td>159 (74.0)</td>
<td/>
<td>164 (73.9)</td>
<td>58 (26.1)</td>
<td/>
</tr>
<tr>
<td>Age</td>
<td/>
<td/>
<td/>
<td>.27<sup><xref ref-type="table-fn" rid="table-fn2-0194599811435052">a</xref></sup></td>
<td/>
<td/>
<td>.50<sup><xref ref-type="table-fn" rid="table-fn2-0194599811435052">a</xref></sup></td>
</tr>
<tr>
<td> Mean age, y</td>
<td>57.9</td>
<td>56.5</td>
<td>58.5</td>
<td/>
<td>58.2</td>
<td>57.0</td>
<td/>
</tr>
<tr>
<td>Gender, No. (%)</td>
<td/>
<td/>
<td/>
<td>.13<sup><xref ref-type="table-fn" rid="table-fn3-0194599811435052">b</xref></sup></td>
<td/>
<td/>
<td>.27<sup><xref ref-type="table-fn" rid="table-fn3-0194599811435052">b</xref></sup></td>
</tr>
<tr>
<td> Females</td>
<td>54 (24.3)</td>
<td>18 (32.1)</td>
<td>35 (22.0)</td>
<td/>
<td>43 (26.2)</td>
<td>11 (19.0)</td>
<td/>
</tr>
<tr>
<td> Males</td>
<td>168 (75.7)</td>
<td>38 (67.9)</td>
<td>124 (78.0)</td>
<td/>
<td>121 (73.8)</td>
<td>47 (81.0)</td>
<td/>
</tr>
<tr>
<td>Tobacco (n = 213), No. (%)</td>
<td/>
<td/>
<td/>
<td>.37<sup><xref ref-type="table-fn" rid="table-fn3-0194599811435052">b</xref></sup></td>
<td/>
<td/>
<td>.11<sup><xref ref-type="table-fn" rid="table-fn3-0194599811435052">b</xref></sup></td>
</tr>
<tr>
<td> User</td>
<td>185 (86.9)</td>
<td>43 (82.7)</td>
<td>135 (87.7)</td>
<td/>
<td>132 (84.6)</td>
<td>53 (93.0)</td>
<td/>
</tr>
<tr>
<td> Nonuser</td>
<td>28 (13.1)</td>
<td>9 (17.3)</td>
<td>19 (12.3)</td>
<td/>
<td>24 (15.4)</td>
<td>4 (7.0)</td>
<td/>
</tr>
<tr>
<td>Alcohol (n = 196), No. (%)</td>
<td/>
<td/>
<td/>
<td>.12<sup><xref ref-type="table-fn" rid="table-fn3-0194599811435052">b</xref></sup></td>
<td/>
<td/>
<td><bold>.007</bold><sup><xref ref-type="table-fn" rid="table-fn3-0194599811435052">b</xref></sup></td>
</tr>
<tr>
<td> None/rare</td>
<td>72 (36.7)</td>
<td>22 (47.8)</td>
<td>48 (33.3)</td>
<td/>
<td>57 (40.4)</td>
<td>15 (27.3)</td>
<td/>
</tr>
<tr>
<td> Moderate/heavy</td>
<td>98 (50.0)</td>
<td>17 (37.0)</td>
<td>78 (54.2)</td>
<td/>
<td>61 (43.3)</td>
<td>37 (67.3)</td>
<td/>
</tr>
<tr>
<td> Historic, quit</td>
<td>26 (13.3)</td>
<td>7 (15.2)</td>
<td>18 (12.5)</td>
<td/>
<td>23 (16.3)</td>
<td>3 (5.5)</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0194599811435052">
<p>Bold values represent statistically significant differences.</p>
</fn>
<fn id="table-fn2-0194599811435052">
<label>a</label>
<p><italic>t</italic> test.</p>
</fn>
<fn id="table-fn3-0194599811435052">
<label>b</label>
<p>χ<sup>2</sup> test.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0194599811435052" position="float">
<label>Table 2.</label>
<caption>
<p>Tumor Characteristics</p>
</caption>
<graphic alternate-form-of="table2-0194599811435052" xlink:href="10.1177_0194599811435052-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th align="center" colspan="3">Cyclin D1 Expression (n = 215)</th>
<th align="center" colspan="3">FADD Expression (n = 222)</th>
</tr>
<tr>
<th/>
<th align="center">All</th>
<th align="center">Low</th>
<th align="center">High</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn5-0194599811435052">a</xref></sup></th>
<th align="center">Low</th>
<th align="center">High</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn5-0194599811435052">a</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients</td>
<td>222 (100.0)</td>
<td>56 (26.0)</td>
<td>159 (74.0)</td>
<td/>
<td>164 (73.9)</td>
<td>58 (26.1)</td>
<td/>
</tr>
<tr>
<td>Primary site</td>
<td/>
<td/>
<td/>
<td>.15</td>
<td/>
<td/>
<td><bold>.005</bold></td>
</tr>
<tr>
<td> Oral cavity</td>
<td>82 (36.9)</td>
<td>13 (23.2)</td>
<td>66 (41.5)</td>
<td/>
<td>59 (36.0)</td>
<td>23 (39.7)</td>
<td/>
</tr>
<tr>
<td> Oropharynx</td>
<td>33 (14.9)</td>
<td>7 (12.5)</td>
<td>24 (15.1)</td>
<td/>
<td>22 (13.4)</td>
<td>11 (19.0)</td>
<td/>
</tr>
<tr>
<td> Hypopharynx</td>
<td>16 (7.2)</td>
<td>5 (8.9)</td>
<td>11 (6.9)</td>
<td/>
<td>7 (4.3)</td>
<td>9 (15.5)</td>
<td/>
</tr>
<tr>
<td> Supraglottis</td>
<td>57 (25.7)</td>
<td>21 (37.5)</td>
<td>36 (22.6)</td>
<td/>
<td>44 (26.8)</td>
<td>13 (22.4)</td>
<td/>
</tr>
<tr>
<td> Glottis</td>
<td>27 (12.2)</td>
<td>8 (14.3)</td>
<td>17 (10.7)</td>
<td/>
<td>25 (15.2)</td>
<td>2 (3.4)</td>
<td/>
</tr>
<tr>
<td> Nasal cavity/sinus</td>
<td>7 (3.2)</td>
<td>2 (3.6)</td>
<td>5 (3.1)</td>
<td/>
<td>7 (4.3)</td>
<td>0</td>
<td/>
</tr>
<tr>
<td>Primary stage</td>
<td/>
<td/>
<td/>
<td>.085</td>
<td/>
<td/>
<td><bold>.019</bold></td>
</tr>
<tr>
<td> T1</td>
<td>30 (13.5)</td>
<td>5 (8.9)</td>
<td>24 (15.1)</td>
<td/>
<td>29 (17.7)</td>
<td>1 (1.7)</td>
<td/>
</tr>
<tr>
<td> T2</td>
<td>72 (32.4)</td>
<td>12 (21.4)</td>
<td>57 (35.8)</td>
<td/>
<td>46 (28.0)</td>
<td>26 (44.8)</td>
<td/>
</tr>
<tr>
<td> T3</td>
<td>58 (26.1)</td>
<td>19 (33.9)</td>
<td>38 (23.9)</td>
<td/>
<td>43 (26.2)</td>
<td>15 (25.9)</td>
<td/>
</tr>
<tr>
<td> T4</td>
<td>51 (23.0)</td>
<td>18 (32.1)</td>
<td>32 (20.1)</td>
<td/>
<td>38 (23.2)</td>
<td>13 (22.4)</td>
<td/>
</tr>
<tr>
<td> Recurrent</td>
<td>11 (5.0)</td>
<td>2 (3.6)</td>
<td>8 (5.0)</td>
<td/>
<td>8 (4.9)</td>
<td>3 (5.2)</td>
<td/>
</tr>
<tr>
<td>Nodal stage</td>
<td/>
<td/>
<td/>
<td>.79</td>
<td/>
<td/>
<td>.068</td>
</tr>
<tr>
<td> N0</td>
<td>122 (55.0)</td>
<td>30 (53.6)</td>
<td>88 (55.3)</td>
<td/>
<td>100 (61.0)</td>
<td>22 (37.9)</td>
<td/>
</tr>
<tr>
<td> N1</td>
<td>24 (10.8)</td>
<td>7 (12.5)</td>
<td>17 (10.7)</td>
<td/>
<td>15 (9.1)</td>
<td>9 (15.5)</td>
<td/>
</tr>
<tr>
<td> N2a</td>
<td>14 (6.3)</td>
<td>3 (5.4)</td>
<td>10 (6.3)</td>
<td/>
<td>7 (4.3)</td>
<td>7 (12.1)</td>
<td/>
</tr>
<tr>
<td> N2b</td>
<td>30 (13.5)</td>
<td>7 (12.5)</td>
<td>23 (14.5)</td>
<td/>
<td>21 (12.8)</td>
<td>9 (15.5)</td>
<td/>
</tr>
<tr>
<td> N2c</td>
<td>18 (8.1)</td>
<td>5 (8.9)</td>
<td>12 (7.5)</td>
<td/>
<td>11 (6.7)</td>
<td>7 (12.1)</td>
<td/>
</tr>
<tr>
<td> N3</td>
<td>3 (1.4)</td>
<td>2 (3.6)</td>
<td>1 (0.6)</td>
<td/>
<td>2 (1.2)</td>
<td>1 (1.7)</td>
<td/>
</tr>
<tr>
<td> Recurrent</td>
<td>11 (5.0)</td>
<td>2 (3.6)</td>
<td>8 (5.0)</td>
<td/>
<td>8 (4.9)</td>
<td>3 (5.2)</td>
<td/>
</tr>
<tr>
<td>Stage group</td>
<td/>
<td/>
<td/>
<td>.13</td>
<td/>
<td/>
<td>.13</td>
</tr>
<tr>
<td> I</td>
<td>26 (11.7)</td>
<td>3 (5.4)</td>
<td>22 (13.8)</td>
<td/>
<td>25 (15.2)</td>
<td>1 (1.7)</td>
<td/>
</tr>
<tr>
<td> II</td>
<td>42 (18.9)</td>
<td>7 (12.5)</td>
<td>33 (20.8)</td>
<td/>
<td>32 (19.5)</td>
<td>10 (17.2)</td>
<td/>
</tr>
<tr>
<td> III</td>
<td>52 (23.4)</td>
<td>15 (26.8)</td>
<td>37 (23.3)</td>
<td/>
<td>36 (22.0)</td>
<td>16 (27.6)</td>
<td/>
</tr>
<tr>
<td> IVA</td>
<td>88 (39.6)</td>
<td>27 (48.2)</td>
<td>58 (36.5)</td>
<td/>
<td>61 (37.2)</td>
<td>27 (46.6)</td>
<td/>
</tr>
<tr>
<td> IVB</td>
<td>3 (1.4)</td>
<td>2 (3.6)</td>
<td>1 (0.6)</td>
<td/>
<td>2 (1.2)</td>
<td>1 (1.7)</td>
<td/>
</tr>
<tr>
<td> Recurrent</td>
<td>11 (5.0)</td>
<td>2 (3.6)</td>
<td>8 (5.0)</td>
<td/>
<td>8 (4.9)</td>
<td>3 (5.2)</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0194599811435052"><p>Values presented as No. (%). Bold values represent statistically significant differences.</p></fn>
<fn id="table-fn5-0194599811435052"><label>a</label><p>χ<sup>2</sup> test.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>As shown in <xref ref-type="table" rid="table1-0194599811435052"><bold>Table 1</bold></xref>, average age, gender, and tobacco use were similar in the low and high subgroups of both cyclin D1 and FADD. Alcohol use was similar in low and high cyclin D1 patients, but high FADD expression was noted to be associated with a greater proportion of moderate/heavy drinkers (<italic>P</italic> = .007).</p>
<p><xref ref-type="table" rid="table2-0194599811435052"><bold>Table 2</bold></xref> summarizes tumor characteristics. For cyclin D1, low- and high-expressing tumor groups had a similar distribution of primary site, T stage, N stage, and stage group. Although not statistically significant, the high cyclin D1–expressing tumor group had more T1 and T2 tumors (50.9%) compared with low expressers (30.3%) and fewer T3 and T4 tumors (44.0% vs 66.0%). <xref ref-type="fig" rid="fig2-0194599811435052"><bold>Figure 2</bold></xref> shows the percentage of high cyclin D1 tumors by anatomic site; modest variability is noted.</p>
<fig id="fig2-0194599811435052" position="float">
<label>Figure 2.</label>
<caption>
<p>Cyclin D1 and FADD expression rates by anatomic site. G, glottis; HP, hypopharynx; NC/S, nasal cavity/sinuses; OC, oral cavity; OP, oropharynx; SG, supraglottis.</p>
</caption>
<graphic xlink:href="10.1177_0194599811435052-fig2.tif"/>
</fig>
<p>For FADD, low- and high-expressing groups were significantly different in terms of primary site and T stage distribution. As shown in <xref ref-type="fig" rid="fig2-0194599811435052"><bold>Figure 2</bold></xref>, 56% of hypopharyngeal primary tumors were high FADD expressers, whereas only 7% of glottis tumors and no nasal cavity/sinus tumors demonstrated high FADD expression. Thus, the distribution of primary sites for low vs high FADD tumors was statistically different (<italic>P</italic> = .005). Similarly, high FADD tumors demonstrated a lower percentage of T1 primaries and a higher percentage of T2 primaries compared with low FADD tumors; thus, the T stage distribution was statistically different in the 2 groups (<italic>P</italic> = .019). Although the N stage distribution was not statistically different between the low and high FADD groups, there were noticeably more N0 tumors in the low FADD group (61.0%) compared with the high FADD group (37.9%). This correlated with a difference in stage grouping, with relatively fewer stage I and more stage IVA tumors in the high FADD group; this also was not statistically significant.</p>
</sec>
<sec id="section8-0194599811435052">
<title>Survival Outcomes</title>
<p><xref ref-type="fig" rid="fig3-0194599811435052"><bold>Figures 3</bold></xref>, <xref ref-type="fig" rid="fig4-0194599811435052"><bold>4</bold></xref>, and <xref ref-type="fig" rid="fig5-0194599811435052"><bold>5</bold></xref> show OS, DSS, and DFS curves segregated for cyclin D1 expression, FADD expression, and combined cyclin D1/FADD expression, respectively. The log-rank test was used to assess statistical significance. Patients with tumors that were strongly positive for cyclin D1 and FADD had reduced overall (OS; <italic>P</italic> = .003 and <italic>P</italic> &lt; .001), disease-specific (DSS; <italic>P</italic> = .039 and <italic>P</italic> &lt; .001), and disease-free (DFS; <italic>P</italic> = .026 and <italic>P</italic> &lt; .001) survival, respectively. Together, the 2 markers effectively stratified OS (<italic>P</italic> &lt; .001), DSS (<italic>P</italic> &lt; .001), and DFS (<italic>P</italic> = .002). <xref ref-type="table" rid="table3-0194599811435052"><bold>Table 3</bold></xref> summarizes these results and also shows the other factors that were significant predictors of survival. In isolation, primary site, N stage, and stage group were statistically associated with OS, DSS, and DFS. In addition, alcohol use was predictive of OS and DSS, and T stage was predictive of DSS. Any history of tobacco use was not a significant predictor of OS, DSS, or DFS (<italic>P</italic> = .196, <italic>P</italic> = .506, and <italic>P</italic> = .556, respectively). This may be because in this cohort, 87% of patients were smokers. However, patient-reported pack-years of tobacco use was also evaluated and showed no correlation with survival (data not shown).</p>
<fig id="fig3-0194599811435052" position="float">
<label>Figure 3.</label>
<caption>
<p>Kaplan-Meier survival by cyclin D1 expression. (A) Overall survival. (B) Disease-specific survival. (C) Disease-free survival.</p>
</caption>
<graphic xlink:href="10.1177_0194599811435052-fig3.tif"/>
</fig>
<fig id="fig4-0194599811435052" position="float">
<label>Figure 4.</label>
<caption>
<p>Kaplan-Meier survival by FADD expression. (A) Overall survival. (B) Disease-specific survival. (C) Disease-free survival.</p>
</caption>
<graphic xlink:href="10.1177_0194599811435052-fig4.tif"/>
</fig>
<fig id="fig5-0194599811435052" position="float">
<label>Figure 5.</label>
<caption>
<p>Kaplan-Meier survival by cyclin D1 and FADD expression. (A) Overall survival. (B) Disease-specific survival. (C) Disease-free survival.</p>
</caption>
<graphic xlink:href="10.1177_0194599811435052-fig5.tif"/>
</fig>
<table-wrap id="table3-0194599811435052" position="float">
<label>Table 3.</label>
<caption>
<p>Univariate Correlation of Patient and Tumor Characteristics with Survival Outcomes</p>
</caption>
<graphic alternate-form-of="table3-0194599811435052" xlink:href="10.1177_0194599811435052-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="3">Log-Rank Test</th>
</tr>
<tr>
<th/>
<th align="center">Overall Survival</th>
<th align="center">Disease-Specific Survival</th>
<th align="center">Disease-Free Survival</th>
</tr>
<tr>
<th align="center">Variable</th>
<th align="center"><italic>P</italic> Value</th>
<th align="center"><italic>P</italic> Value</th>
<th align="center"><italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclin D1</td>
<td><bold>.003</bold></td>
<td><bold>.039</bold></td>
<td><bold>.026</bold></td>
</tr>
<tr>
<td>FADD</td>
<td><bold>&lt;.001</bold></td>
<td><bold>&lt;.001</bold></td>
<td><bold>&lt;.001</bold></td>
</tr>
<tr>
<td>Cyclin D1 + FADD</td>
<td><bold>&lt;.001</bold></td>
<td><bold>&lt;.001</bold></td>
<td><bold>.002</bold></td>
</tr>
<tr>
<td>Age by decade</td>
<td>.093</td>
<td>.895</td>
<td>.628</td>
</tr>
<tr>
<td>Tobacco use</td>
<td>.196</td>
<td>.506</td>
<td>.556</td>
</tr>
<tr>
<td>Alcohol use</td>
<td><bold>.004</bold></td>
<td><bold>.042</bold></td>
<td>.504</td>
</tr>
<tr>
<td>Primary site</td>
<td><bold>&lt;.001</bold></td>
<td><bold>&lt;.001</bold></td>
<td><bold>.002</bold></td>
</tr>
<tr>
<td>T stage</td>
<td>.083</td>
<td><bold>&lt;.001</bold></td>
<td>.090</td>
</tr>
<tr>
<td>N stage</td>
<td><bold>&lt;.001</bold></td>
<td><bold>&lt;.001</bold></td>
<td><bold>&lt;.001</bold></td>
</tr>
<tr>
<td>Stage group</td>
<td><bold>&lt;.001</bold></td>
<td><bold>&lt;.001</bold></td>
<td><bold>&lt;.001</bold></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-0194599811435052">
<p>Bold values represent statistically significant differences.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>To evaluate the interdependence of these variables, a Cox regression analysis was performed. For each type of survival curve, factors that were significant predictors in isolation by the log-rank test were included in the multivariate model, as shown in <xref ref-type="table" rid="table4-0194599811435052"><bold>Tables 4</bold></xref>, <xref ref-type="table" rid="table5-0194599811435052"><bold>5</bold></xref>, and <xref ref-type="table" rid="table6-0194599811435052"><bold>6</bold></xref>. For OS (<xref ref-type="table" rid="table4-0194599811435052"><bold>Table 4</bold></xref>), cyclin D1, FADD, and N stage were independent predictors of outcome (<italic>P</italic> = .007, <italic>P</italic> = .010, <italic>P</italic> = .037, respectively). For DSS (<xref ref-type="table" rid="table5-0194599811435052"><bold>Table 5</bold></xref>), FADD and N stage were independent predictors (<italic>P</italic> = .013 and <italic>P</italic> = .002, respectively). Similarly, for DFS (<xref ref-type="table" rid="table6-0194599811435052"><bold>Table 6</bold></xref>), FADD and N stage were statistically significant (<italic>P</italic> = .006 and <italic>P</italic> &lt; .001, respectively).</p>
<table-wrap id="table4-0194599811435052" position="float">
<label>Table 4.</label>
<caption>
<p>Multivariate Correlation of Patient and Tumor Characteristics with Overall Survival</p>
</caption>
<graphic alternate-form-of="table4-0194599811435052" xlink:href="10.1177_0194599811435052-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="4">Cox Regression: Overall Survival</th>
</tr>
<tr>
<th align="left">Variable</th>
<th align="left">Coefficient β (SE)</th>
<th align="left">Wald χ<sup>2</sup></th>
<th align="left"><italic>P</italic> Value</th>
<th align="left">Odds Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclin D1</td>
<td><bold>0.665 (0.247)</bold></td>
<td><bold>7.227</bold></td>
<td><bold>.007</bold></td>
<td><bold>1.94 (1.20-3.16)</bold></td>
</tr>
<tr>
<td>FADD</td>
<td><bold>0.545 (0.211)</bold></td>
<td><bold>6.685</bold></td>
<td><bold>.010</bold></td>
<td><bold>1.72 (1.14-2.60)</bold></td>
</tr>
<tr>
<td>Alcohol use</td>
<td>0.187 (0.138)</td>
<td>1.837</td>
<td>.175</td>
<td>1.21 (0.92-1.58)</td>
</tr>
<tr>
<td>Primary site</td>
<td>0.024 (0.058)</td>
<td>0.177</td>
<td>.674</td>
<td>1.02 (0.91-1.15)</td>
</tr>
<tr>
<td>N stage</td>
<td><bold>0.476 (0.228)</bold></td>
<td><bold>4.350</bold></td>
<td><bold>.037</bold></td>
<td><bold>1.61 (1.03-2.52)</bold></td>
</tr>
<tr>
<td>Stage group</td>
<td>0.383 (0.245)</td>
<td>2.454</td>
<td>.117</td>
<td>1.47 (0.91-2.37)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-0194599811435052">
<p>Abbreviations: CI, confidence interval; SE, standard error. Bold values represent statistically significant differences.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table5-0194599811435052" position="float">
<label>Table 5.</label>
<caption>
<p>Multivariate Correlation of Patient and Tumor Characteristics with Disease-Specific Survival</p>
</caption>
<graphic alternate-form-of="table5-0194599811435052" xlink:href="10.1177_0194599811435052-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="4">Cox Regression: Disease-Specific Survival</th>
</tr>
<tr>
<th align="left">Variable</th>
<th align="left">Coefficient β (SE)</th>
<th align="left">Wald χ<sup>2</sup></th>
<th align="left"><italic>P</italic> Value</th>
<th align="left">Odds Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclin D1</td>
<td>0.663 (0.397)</td>
<td>2.783</td>
<td>.095</td>
<td>1.94 (0.89-4.23)</td>
</tr>
<tr>
<td>FADD</td>
<td><bold>0.730 (0.295)</bold></td>
<td><bold>6.133</bold></td>
<td><bold>.013</bold></td>
<td><bold>2.07 (1.16-3.70)</bold></td>
</tr>
<tr>
<td>Alcohol use</td>
<td>0.285 (0.206)</td>
<td>1.912</td>
<td>.167</td>
<td>1.33 (0.89-1.99)</td>
</tr>
<tr>
<td>Primary site</td>
<td>−0.004 (0.091)</td>
<td>0.002</td>
<td>.964</td>
<td>1.00 (0.83-1.19)</td>
</tr>
<tr>
<td>T stage</td>
<td>0.266 (0.159)</td>
<td>2.809</td>
<td>.094</td>
<td>1.30 (0.96-1.78)</td>
</tr>
<tr>
<td>N stage</td>
<td><bold>1.109 (0.352)</bold></td>
<td><bold>9.911</bold></td>
<td><bold>.002</bold></td>
<td><bold>3.03 (1.52-6.04)</bold></td>
</tr>
<tr>
<td>Stage group</td>
<td>0.394 (0.493)</td>
<td>0.638</td>
<td>.424</td>
<td>1.48 (0.56-3.89)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn8-0194599811435052">
<p>Abbreviations: CI, confidence interval; SE, standard error. Bold values represent statistically significant differences.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table6-0194599811435052" position="float">
<label>Table 6.</label>
<caption>
<p>Multivariate Correlation of Patient and Tumor Characteristics with Disease-Free Survival</p>
</caption>
<graphic alternate-form-of="table6-0194599811435052" xlink:href="10.1177_0194599811435052-table6.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="4">Cox Regression: Disease-Free Survival</th>
</tr>
<tr>
<th align="left">Variable</th>
<th align="left">Coefficient β (SE)</th>
<th align="left">Wald χ<sup>2</sup></th>
<th align="left"><italic>P</italic> Value</th>
<th align="left">Odds Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclin D1</td>
<td>0.513 (0.294)</td>
<td>3.038</td>
<td>.081</td>
<td>1.67 (0.94-2.98)</td>
</tr>
<tr>
<td>FADD</td>
<td><bold>0.647 (0.235)</bold></td>
<td><bold>7.601</bold></td>
<td><bold>.006</bold></td>
<td><bold>1.91 (1.21-3.02)</bold></td>
</tr>
<tr>
<td>Primary Site</td>
<td>0.110 (0.067)</td>
<td>2.745</td>
<td>.098</td>
<td>1.12 (0.98-1.27)</td>
</tr>
<tr>
<td>N stage</td>
<td><bold>1.079 (0.295)</bold></td>
<td><bold>13.397</bold></td>
<td><bold>&lt;.001</bold></td>
<td><bold>2.94 (1.65-5.24)</bold></td>
</tr>
<tr>
<td>Stage group</td>
<td>−0.307 (0.298)</td>
<td>1.055</td>
<td>.304</td>
<td>0.74 (0.41-1.32)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn9-0194599811435052">
<p>Abbreviations: CI, confidence interval; SE, standard error. Bold values represent statistically significant differences.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section9-0194599811435052" sec-type="discussion">
<title>Discussion</title>
<p>Multiple genes within the 11q13 locus, including cyclin D1, have been correlated with poor prognosis.<sup><xref ref-type="bibr" rid="bibr7-0194599811435052">7</xref><xref ref-type="bibr" rid="bibr8-0194599811435052"/>-<xref ref-type="bibr" rid="bibr9-0194599811435052">9</xref>,<xref ref-type="bibr" rid="bibr11-0194599811435052">11</xref>,<xref ref-type="bibr" rid="bibr14-0194599811435052">14</xref>,<xref ref-type="bibr" rid="bibr22-0194599811435052">22</xref>,<xref ref-type="bibr" rid="bibr23-0194599811435052">23</xref></sup> Specifically, decreased OS in laryngeal SCC has been noted with elevated levels of cyclin D1,<sup><xref ref-type="bibr" rid="bibr23-0194599811435052">23</xref></sup> and a correlation has been noted between specific genes within 11q13, among them cyclin D1, and cervical lymph node metastases.<sup><xref ref-type="bibr" rid="bibr22-0194599811435052">22</xref></sup> Miyamoto et al<sup><xref ref-type="bibr" rid="bibr14-0194599811435052">14</xref></sup> demonstrated decreased OS and DFS in patients with amplification of CCND1, the gene encoding cyclin D1. Our findings further support the negative implications of cyclin D1 overexpression by correlating it with a statistically significant decrease in OS, DSS, and DFS. Given the promitotic role of cyclin D1 in the cell cycle, it follows logically that elevated levels should result in more rapid or aggressive tumor growth. This phenomenon has been demonstrated by overexpressing cyclin D1 with resultant increased cellular proliferation in vitro.<sup><xref ref-type="bibr" rid="bibr24-0194599811435052">24</xref>,<xref ref-type="bibr" rid="bibr25-0194599811435052">25</xref></sup> In addition, cyclin D1 inhibition via application of antisense cyclin D1 during G1 phase results in decreased proliferation and tumorigenicity in nude mice.<sup><xref ref-type="bibr" rid="bibr26-0194599811435052">26</xref>,<xref ref-type="bibr" rid="bibr27-0194599811435052">27</xref></sup></p>
<p>FADD is a proapoptotic adaptor protein that confers a survival advantage to cells when it is mutated or absent due to altered death receptor–mediated apoptosis pathways.<sup><xref ref-type="bibr" rid="bibr19-0194599811435052">19</xref></sup> Theoretically, elevated expression of FADD should result in increased caspase activation and apoptosis. However, several recent studies have demonstrated a more complex and diverse range of functions for FADD, including effects on survival, proliferation, cell cycle progression, innate immunity, inflammation, and autophagy.<sup><xref ref-type="bibr" rid="bibr19-0194599811435052">19</xref></sup> The functional behavior of FADD appears to be dependent, at least in part, on cellular localization (ie, nuclear vs cytoplasmic), as well as phosphorylation at Ser-194. The present study does not clarify whether increased FADD levels functionally affect the behavior of HNSCC tumors at the cellular level vs simply being a marker of cellular activity driven by other pathways. However, the correlation of high FADD protein expression with earlier tumor recurrence and significantly worse survival may support the concept of a much more complex role for FADD than a simple cog in the apoptosis machinery.</p>
<p>Along these lines, it was interesting to note that increased FADD expression is statistically associated with greater alcohol consumption. Although there is very little in the literature to shed light on this relationship, Castaneda and Rosin-Steiner<sup><xref ref-type="bibr" rid="bibr28-0194599811435052">28</xref></sup> demonstrated in HepG2 hepatocellular carcinoma cells that ethanol exposure induces apoptosis in part via FADD activity. In their study, FADD expression doubled at 24 hours after ethanol exposure; however, apoptosis was induced by this exposure. Interestingly, an earlier study demonstrated that epidermal growth factor (EGF) stimulation could protect the liver from alcohol-induced injury by preventing apoptosis.<sup><xref ref-type="bibr" rid="bibr29-0194599811435052">29</xref></sup> Given that overexpression of EGFR is nearly ubiquitous in HNSCC and constitutive activity of the receptor is quite common, one could conceive that ethanol exposure leads to elevated FADD levels in HNSCC cells without the predicted apoptotic response.</p>
<p>The present study demonstrates a very clear association of cyclin D1 and FADD overexpression with poor prognosis; thus, they may be useful biomarkers for HNSCC. It is possible that their prognostic significance is simply due to 11q13 amplification. However, FADD and cyclin D1 expression differed in several ways (eg, FADD correlation with alcohol use and primary site, which was not noted for cyclin D1), suggesting that their contributions to prognosis are independent of one another, and they may play a functional role in the aggressiveness of these tumors independent of 11q13 amplification. This is supported by the finding of independence in the Cox regression analysis. The caveat, of course, is that they were only independent predictors for OS, and thus one could be predicting disease-specific mortality (likely FADD, because it was an independent predictor of DSS and DFS), whereas the other is predicting non-disease-related mortality. If the noted cyclin D1 and FADD overexpression are due to important functional effects leading to transformation and progression, they could be potential targets for molecular targeted therapy. On the other hand, Sugahara et al<sup><xref ref-type="bibr" rid="bibr22-0194599811435052">22</xref></sup> demonstrated that in HNSCCs that demonstrate 11q13 amplification, gene amplification within that locus occurs in a nonuniform manner. The nonuniform amplification of proteins within 11q13 may also explain the variability in consequences for patient survival between high FADD and cyclin D1 expression as opposed to variable cellular roles of these proteins.</p>
<p>Overall, it is unclear whether FADD and cyclin D1 are mere biomarkers for 11q13 amplification. If so, their expression may represent overall genomic instability that is the root cause of the noted decrease in survival rather than a molecular effect of FADD or cyclin D1 on tumor cell survival, growth, and progression. Interestingly, high FADD/high cyclin D1 expressers had the same survival patterns as high FADD/low cyclin D1 expressers, indicating that high FADD expression was associated with poor survival regardless of cyclin D1 expression. However, in low FADD expressers, segregation by cyclin D1 expression resulted in groups with improved survival (low cyclin D1) and poorer survival (high cyclin D1). Thus, the expression levels of the 2 proteins have differential and context-specific impact on survival, suggesting that our findings cannot be explained by genomic instability alone. If this is true and both FADD and cyclin D1 play a role in encouraging aggressive behavior of the tumors, they would certainly represent additional proteins for targeted modality therapy. Further research into their role in HNSCC is warranted.</p>
<p>There are limitations to our study. First, the retrospective clinical data retrieval creates a collection bias; some records were simply inaccessible, and others had incomplete and possibly inaccurate records. We attempted to minimize reporting bias by blinding the individuals performing clinical data collection to the IHC findings. Second, we determined arbitrary cutoffs in staining intensity to create our subgroups. Fortunately, these cutoffs are well defined and were consistently applied, and they should be reasonably reproducible in other settings. In addition, IHC has inherent limitations due to the subjective, nonquantitative evaluation, as well as technical problems when performed on archived tissue of variable quality. However, the TMA approach minimizes these problems as staining is performed consistently across all samples simultaneously. Although other studies postulate that detection of DNA amplification more accurately predicts prognosis and should be used in lieu of IHC,<sup><xref ref-type="bibr" rid="bibr30-0194599811435052">30</xref></sup> abundant genes do not necessarily produce abundant protein, and determination of actual protein overexpression is paramount. Compared with tissue sample analysis by immunoblotting techniques, IHC allows for confirmation that the protein of interest is expressed in the tumor rather than other tissues in the specimen. It is important to note that elevated protein levels, by either technique, may result not only from changes in the rates of transcription and/or translation but also from mutations that alter protein stability or cellular conditions that alter the rate of degradation. Unfortunately, the pool of specimens was strongly biased toward tumors that were resected, thus providing adequate tissue for inclusion in the TMA; this may ignore a large subset of HNSCCs that were treated by nonsurgical approaches. However, given the limitations, strong, unambiguous correlations were found between the proteins of interest and survival outcomes. This study thus provides support for prospective evaluation of FADD and/or cyclin D1 as a biomarker in the management of patients with HNSCC.</p>
<p>Our data demonstrate decreased DSS and DFS in patients with high expression of cyclin D1 or FADD and may identify patients who should be selected (or not) for more aggressive therapy and/or shorter follow-up intervals with more frequent imaging in the first 2 years. High FADD appears to be associated with continued decreasing survival at and beyond the 5-year mark. Consequently, patients with tumors demonstrating high FADD expression may be good candidates for extended follow-up.</p>
</sec>
<sec id="section10-0194599811435052" sec-type="conclusions">
<title>Conclusion</title>
<p>High cyclin D1 and FADD expression predict worse OS, DSS, and DFS in patients with HNSCC and thus have potential implications for prognostication, treatment planning, and posttreatment observation. Further study is needed to determine if these proteins predict response to different treatment approaches or assist in selecting patients for multimodality therapy. Ultimately, cyclin D1 and FADD may figure prominently in the development of individualized approaches to HNSCC management.</p>
</sec>
<sec id="section11-0194599811435052">
<title>Author Contributions</title>
<p><bold>Jk J. Rasamny</bold>, study design, data acquisition, data analysis and interpretation, article drafting, article revision, final approval; <bold>Amir Allak</bold>, study design, data acquisition, article revision, final approval; <bold>Kaelyn A. Krook</bold>, study design, data acquisition, data analysis and interpretation, article drafting, article revision, final approval; <bold>Vickie Y. Jo</bold>, data acquisition, article revision, final approval; <bold>Maria L. Policarpio-Nicolas</bold>, data acquisition, article revision, final approval; <bold>Heather M. Sumner</bold>, data acquisition, article revision, final approval; <bold>Christopher A. Moskaluk</bold>, data acquisition, article revision, final approval; <bold>Henry F. Frierson Jr</bold> study design, data acquisition, data interpretation, article revision, final approval; <bold>Mark J. Jameson</bold>, study design, data analysis and interpretation, article drafting, article revision, final approval.</p>
</sec>
<sec id="section12-0194599811435052">
<title>Disclosures</title>
<p><bold>Competing interests</bold>: None.</p>
<p><bold>Sponsorships</bold>: None.</p>
<p><bold>Funding source</bold>: None.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="presented-at">
<p>No sponsorships or competing interests have been disclosed for this article.</p>
<p>This article was presented at the 2011 AAO-HNSF Annual Meeting &amp; OTO EXPO; September 11-14, 2011; San Francisco, California.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0194599811435052">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jemal</surname><given-names>A</given-names></name>
<name><surname>Siegel</surname><given-names>R</given-names></name>
<name><surname>Xu</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Cancer statistics, 2010</article-title>. <source>CA Cancer J Clin</source>. <year>2010</year>;<volume>60</volume>(<issue>5</issue>):<fpage>277</fpage>-<lpage>300</lpage>.</citation>
</ref>
<ref id="bibr2-0194599811435052">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gold</surname><given-names>KA</given-names></name>
<name><surname>Kim</surname><given-names>ES</given-names></name>
</person-group>. <article-title>Role of molecular markers and gene profiling in head and neck cancers</article-title>. <source>Curr Opin Oncol</source>. <year>2009</year>;<volume>21</volume>(<issue>3</issue>):<fpage>206</fpage>-<lpage>211</lpage>.</citation>
</ref>
<ref id="bibr3-0194599811435052">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Renan</surname><given-names>MJ</given-names></name>
</person-group>. <article-title>How many mutations are required for tumorigenesis? Implications from human cancer data</article-title>. <source>Mol Carcinog</source>. <year>1993</year>;<volume>7</volume>(<issue>3</issue>):<fpage>139</fpage>-<lpage>146</lpage>.</citation>
</ref>
<ref id="bibr4-0194599811435052">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Califano</surname><given-names>J</given-names></name>
<name><surname>van der Riet</surname><given-names>P</given-names></name>
<name><surname>Westra</surname><given-names>W</given-names></name>
<etal/>
</person-group>. <article-title>Genetic progression model for head and neck cancer: implications for field cancerization</article-title>. <source>Cancer Res</source>. <year>1996</year>;<volume>56</volume>(<issue>11</issue>):<fpage>2488</fpage>-<lpage>2492</lpage>.</citation>
</ref>
<ref id="bibr5-0194599811435052">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ha</surname><given-names>PK</given-names></name>
<name><surname>Benoit</surname><given-names>NE</given-names></name>
<name><surname>Yochem</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>A transcriptional progression model for head and neck cancer</article-title>. <source>Clin Cancer Res</source>. <year>2003</year>;<volume>9</volume>(<issue>8</issue>):<fpage>3058</fpage>-<lpage>3064</lpage>.</citation>
</ref>
<ref id="bibr6-0194599811435052">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gollin</surname><given-names>SM</given-names></name>
</person-group>. <article-title>Chromosomal alterations in squamous cell carcinomas of the head and neck: window to the biology of disease</article-title>. <source>Head Neck</source>. <year>2001</year>;<volume>23</volume>(<issue>3</issue>):<fpage>238</fpage>-<lpage>253</lpage>.</citation>
</ref>
<ref id="bibr7-0194599811435052">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y</given-names></name>
<name><surname>Tondravi</surname><given-names>M</given-names></name>
<name><surname>Liu</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Cortactin potentiates bone metastasis of breast cancer cells</article-title>. <source>Cancer Res</source>. <year>2001</year>;<volume>61</volume>(<issue>18</issue>):<fpage>6906</fpage>-<lpage>6911</lpage>.</citation>
</ref>
<ref id="bibr8-0194599811435052">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Komatsu</surname><given-names>Y</given-names></name>
<name><surname>Hibi</surname><given-names>K</given-names></name>
<name><surname>Kodera</surname><given-names>Y</given-names></name>
<name><surname>Akiyama</surname><given-names>S</given-names></name>
<name><surname>Ito</surname><given-names>K</given-names></name>
<name><surname>Nakao</surname><given-names>A</given-names></name>
</person-group>. <article-title>TAOS1, a novel marker for advanced esophageal squamous cell carcinoma</article-title>. <source>Anticancer Res</source>. <year>2006</year>;<volume>26</volume>(<issue>3A</issue>):<fpage>2029</fpage>-<lpage>2032</lpage>.</citation>
</ref>
<ref id="bibr9-0194599811435052">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Luo</surname><given-names>ML</given-names></name>
<name><surname>Shen</surname><given-names>XM</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>Amplification and overexpression of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance</article-title>. <source>Cancer Res</source>. <year>2006</year>;<volume>66</volume>(<issue>24</issue>):<fpage>11690</fpage>-<lpage>11699</lpage>.</citation>
</ref>
<ref id="bibr10-0194599811435052">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaminagakura</surname><given-names>E</given-names></name>
<name><surname>Werneck da Cunha</surname><given-names>I</given-names></name>
<name><surname>Soares</surname><given-names>FA</given-names></name> <name><surname>Nishimoto</surname><given-names>IN</given-names></name>
<name><surname>Kowalski</surname><given-names>LP</given-names></name>
</person-group>. <article-title>CCND1 amplification and protein overexpression in oral squamous cell carcinoma of young patients. Head Neck</article-title>. <year>2011</year>;<volume>33</volume>(<issue>10</issue>):<fpage>1413</fpage>-<lpage>1419</lpage>.</citation>
</ref>
<ref id="bibr11-0194599811435052">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bova</surname><given-names>RJ</given-names></name>
<name><surname>Quinn</surname><given-names>DI</given-names></name>
<name><surname>Nankervis</surname><given-names>JS</given-names></name>
<etal/>
</person-group>. <article-title>Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue</article-title>. <source>Clin Cancer Res</source>. <year>1999</year>;<volume>5</volume>(<issue>10</issue>):<fpage>2810</fpage>-<lpage>2819</lpage>.</citation>
</ref>
<ref id="bibr12-0194599811435052">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carlos</surname><given-names>de</given-names></name>
<name><surname>Vincente</surname><given-names>J</given-names></name>
<name><surname>Herrero-Zapatero</surname><given-names>A</given-names></name>
<name><surname>Fresno</surname><given-names>MF</given-names></name>
<name><surname>López-Arranz</surname><given-names>JS</given-names></name>
</person-group>. <article-title>Expression of cyclin D1 and Ki-67 in squamous cell carcinoma of the oral cavity: clinicopathological and prognostic significance</article-title>. <source>Oral Oncol</source>. <year>2002</year>;<volume>38</volume>(<issue>3</issue>):<fpage>301</fpage>-<lpage>308</lpage>.</citation>
</ref>
<ref id="bibr13-0194599811435052">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mineta</surname><given-names>H</given-names></name>
<name><surname>Miura</surname><given-names>K</given-names></name>
<name><surname>Takebayashi</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Cyclin D1 overexpression correlates with poor prognosis in patients with tongue squamous cell carcinoma</article-title>. <source>Oral Oncol</source>. <year>2000</year>;<volume>36</volume>(<issue>2</issue>):<fpage>194</fpage>-<lpage>198</lpage>.</citation>
</ref>
<ref id="bibr14-0194599811435052">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miyamoto</surname><given-names>R</given-names></name>
<name><surname>Uzawa</surname><given-names>N</given-names></name>
<name><surname>Nagaoka</surname><given-names>S</given-names></name>
<name><surname>Hirata</surname><given-names>Y</given-names></name>
<name><surname>Amagasa</surname><given-names>T</given-names></name>
</person-group>. <article-title>Prognostic significance of cyclin D1 amplification and overexpression in oral squamous cell carcinomas</article-title>. <source>Oral Oncol</source>. <year>2003</year>;<volume>39</volume>(<issue>6</issue>):<fpage>610</fpage>-<lpage>618</lpage>.</citation>
</ref>
<ref id="bibr15-0194599811435052">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fortin</surname><given-names>A</given-names></name>
<name><surname>Guerry</surname><given-names>M</given-names></name>
<name><surname>Guerry</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Chromosome 11q13 gene amplifications in oral and oropharyngeal carcinomas: no correlation with subclinical lymph node invasion and disease recurrence</article-title>. <source>Clin Cancer Res</source>. <year>1997</year>;<volume>3</volume>(<issue>9</issue>):<fpage>1609</fpage>-<lpage>1614</lpage>.</citation>
</ref>
<ref id="bibr16-0194599811435052">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smith</surname><given-names>BD</given-names></name>
<name><surname>Smith</surname><given-names>GL</given-names></name>
<name><surname>Carter</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>Molecular marker expression in oral and oropharyngeal squamous cell carcinoma</article-title>. <source>Arch Otolaryngol Head Neck Surg</source>. <year>2001</year>;<volume>127</volume>(<issue>7</issue>):<fpage>780</fpage>-<lpage>785</lpage>.</citation>
</ref>
<ref id="bibr17-0194599811435052">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Freier</surname><given-names>K</given-names></name>
<name><surname>Joos</surname><given-names>S</given-names></name>
<name><surname>Flechtenmacher</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma</article-title>. <source>Cancer Res</source>. <year>2003</year>;<volume>63</volume>(<issue>6</issue>):<fpage>1179</fpage>-<lpage>1182</lpage>.</citation>
</ref>
<ref id="bibr18-0194599811435052">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tourneur</surname><given-names>L</given-names></name>
<name><surname>Chiocchia</surname><given-names>G</given-names></name>
</person-group>. <article-title>FADD: a regulator of life and death</article-title>. <source>Trends Immunol</source>. <year>2010</year>;<volume>31</volume>(<issue>7</issue>):<fpage>260</fpage>-<lpage>269</lpage>.</citation>
</ref>
<ref id="bibr19-0194599811435052">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tourneur</surname><given-names>L</given-names></name>
<name><surname>Buzyn</surname><given-names>A</given-names></name>
<name><surname>Chiocchia</surname><given-names>G</given-names></name>
</person-group>. <article-title>FADD adaptor in cancer</article-title>. <source>Med Immunol</source>. <year>2005</year>;<volume>4</volume>(<issue>1</issue>):<fpage>1</fpage>.</citation>
</ref>
<ref id="bibr20-0194599811435052">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cheuk</surname><given-names>W</given-names></name>
<name><surname>Wong</surname><given-names>KO</given-names></name>
<name><surname>Wong</surname><given-names>CS</given-names></name>
<name><surname>Chan</surname><given-names>JK</given-names></name>
</person-group>. <article-title>Consistent immunostaining for cyclin D1 can be achieved on a routine basis using a newly available rabbit monoclonal antibody</article-title>. <source>Am J Surg Pathol</source>. <year>2004</year>;<volume>28</volume>(<issue>6</issue>):<fpage>801</fpage>-<lpage>807</lpage>.</citation>
</ref>
<ref id="bibr21-0194599811435052">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>G</given-names></name>
<name><surname>Bhojani</surname><given-names>MS</given-names></name>
<name><surname>Heaford</surname><given-names>AC</given-names></name>
<etal/>
</person-group>. <article-title>Phosphorylated FADD induces NF-kappaB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2005</year>;<volume>102</volume>(<issue>35</issue>):<fpage>12507</fpage>-<lpage>12512</lpage>.</citation>
</ref>
<ref id="bibr22-0194599811435052">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sugahara</surname><given-names>K</given-names></name>
<name><surname>Michikawa</surname><given-names>Y</given-names></name>
<name><surname>Ishikawa</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>Combination effects of distinct cores in 11q13 amplification region on cervical lymph node metastasis of oral squamous cell carcinoma</article-title>. <source>Int J Oncol</source>. <year>2011</year>;<volume>39</volume>(<issue>4</issue>):<fpage>761</fpage>-<lpage>769</lpage>.</citation>
</ref>
<ref id="bibr23-0194599811435052">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bellacosa</surname><given-names>A</given-names></name>
<name><surname>Almadori</surname><given-names>G</given-names></name>
<name><surname>Cavallo</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Cyclin D1 gene amplification in human laryngeal squamous cell carcinomas: prognostic significance and clinical implications</article-title>. <source>Clin Cancer Res</source>. <year>1996</year>;<volume>2</volume>(<issue>1</issue>):<fpage>175</fpage>-<lpage>180</lpage>.</citation>
</ref>
<ref id="bibr24-0194599811435052">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Quelle</surname><given-names>DE</given-names></name>
<name><surname>Ashmun</surname><given-names>RA</given-names></name>
<name><surname>Shurtleff</surname><given-names>SA</given-names></name>
<etal/>
</person-group>. <article-title>Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts</article-title>. <source>Genes Dev</source>. <year>1993</year>;<volume>7</volume>(<issue>8</issue>):<fpage>1559</fpage>-<lpage>1571</lpage>.</citation>
</ref>
<ref id="bibr25-0194599811435052">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>W</given-names></name>
<name><surname>Kahn</surname><given-names>SM</given-names></name>
<name><surname>Zhou</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression</article-title>. <source>Oncogene</source>. <year>1993</year>;<volume>8</volume>(<issue>12</issue>):<fpage>3447</fpage>-<lpage>3457</lpage>.</citation>
</ref>
<ref id="bibr26-0194599811435052">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>P</given-names></name>
<name><surname>Jiang</surname><given-names>W</given-names></name>
<name><surname>Zhang</surname><given-names>YJ</given-names></name>
<etal/>
</person-group>. <article-title>Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells</article-title>. <source>Oncogene</source>. <year>1995</year>;<volume>11</volume>(<issue>3</issue>):<fpage>571</fpage>-<lpage>580</lpage>.</citation>
</ref>
<ref id="bibr27-0194599811435052">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arber</surname><given-names>N</given-names></name>
<name><surname>Doki</surname><given-names>Y</given-names></name>
<name><surname>Han</surname><given-names>EK</given-names></name>
<etal/>
</person-group>. <article-title>Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells</article-title>. <source>Cancer Res</source>. <year>1997</year>;<volume>57</volume>(<issue>8</issue>):<fpage>1569</fpage>-<lpage>1574</lpage>.</citation>
</ref>
<ref id="bibr28-0194599811435052">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Castaneda</surname><given-names>F</given-names></name>
<name><surname>Rosin-Steiner</surname><given-names>S</given-names></name>
</person-group>. <article-title>Low concentration of ethanol induces apoptosis in HepG2 cells: role of various signal transduction pathways</article-title>. <source>Int J Med Sci</source>. <year>2006</year>;<volume>3</volume>(<issue>4</issue>):<fpage>160</fpage>-<lpage>167</lpage>.</citation>
</ref>
<ref id="bibr29-0194599811435052">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Deaciuc</surname><given-names>IV</given-names></name>
<name><surname>D’Souza</surname><given-names>NB</given-names></name>
<name><surname>Burikhanov</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Epidermal growth factor protects the liver against alcohol-induced injury and sensitization to bacterial lipopolysaccharide</article-title>. <source>Alcohol Clin Exp Res</source>. <year>2002</year>;<volume>26</volume>(<issue>6</issue>):<fpage>864</fpage>-<lpage>874</lpage>.</citation>
</ref>
<ref id="bibr30-0194599811435052">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kyomoto</surname><given-names>R</given-names></name>
<name><surname>Kumazawa</surname><given-names>H</given-names></name>
<name><surname>Toda</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>Cyclin-D1-gene amplification is a more potent prognostic factor than its protein over-expression in human head-and-neck squamous-cell carcinoma</article-title>. <source>Int J Cancer</source>. <year>1997</year>;<volume>74</volume>(<issue>6</issue>):<fpage>576</fpage>-<lpage>581</lpage>.</citation>
</ref></ref-list>
</back>
</article>